BioSpace News Archive

A new study from the Family Heart Foundation, a leading research and advocacy organization, showed the diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH) is delayed, and often occurs after a heart attack or early atherosclerotic cardiovascular disease (ASCVD).

3M announced it has entered into agreements to sell certain assets associated with its dental local anesthetic portfolio, based in Seefeld, Germany, to Pierrel S.p.A., a global provider of services for the pharmaceutical industry, for a purchase price of $70 million, subject to closing and other adjustments.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on May 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 8 individuals hired by Acutus in April 2023.

Viracta Therapeutics, Inc., a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced that Chief Medical Officer, Lisa Rojkjaer, M.D., will be leaving the company to pursue another opportunity, effective May 5, 2023.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on May 1, 2023 as inducement material to such employee entering into employment with KalVista.

Zimmer Biomet Holdings, Inc. today reported financial results for the quarter ended March 31, 2023.

American Clinical Research Services, founded in 2022 to improve the quality of life for millions of Americans through scientific research, announced Dustin Owen has been appointed as the new Chief Executive Officer.

SciSparc Ltd today announced that the last patient enrolled in the Company’s Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease (“AD”) and agitation, completed its treatment.

PharmaTher Holdings Ltd. today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (“FDA”) for KETARX™ (ketamine) for the treatment for levodopa-induced dyskinesia in Parkinson’s disease (“LID-PD”).

Enveric Biosciences, Inc. today announced its support of Mental Health Awareness Month this May as the company advances its novel development programs to improve the treatment of mental health disorders.